Pre-market Hot Trades in US Stocks
Amrize, up 16.38% in pre-market trading, has no significant news recently. The trading is active with clear capital flow, and considering the sector and industry trends, the stock shows significant volatility, with specific reasons needing further observation.
Webus is down 9.06% in pre-market trading. Based on recent news,
<ol>
<li>
On December 24, Webus International Limited announced its expansion into the US outdoor smart devices and robotics market. This move was interpreted by the market as a strategic transformation of the company, leading to fluctuations in investor sentiment and a decline in stock price.
</li>
<li>
On December 24, Webus provided high-end driver services, personalized itineraries, and blockchain travel products through its flagship brand Wetour Travel Tech LLC and regional subsidiaries. Although this news indicates the company's diversification, it failed to boost market confidence, and the stock price continued to decline.
</li>
<li>
On December 24, Webus International Limited released a press release detailing the company's recent business developments and strategic direction. Despite the company's active expansion into new markets, investors remain skeptical about its future profitability, leading to a decline in stock price. The market's doubts about the company's strategic transformation have caused stock price fluctuations.
</li>
</ol>
Top Gainers in Pre-market US Stocks
Can-Fite BioPharma is up 64.23% in pre-market trading. Based on recent news,
<ol>
<li>
On December 26, Can-Fite BioPharma announced that the Brazilian Patent Office granted it a patent for its A3 adenosine receptor agonist for the treatment of sexual dysfunction. This patent provides protection for the company's intellectual property in Brazil and further strengthens its global patent portfolio. This news has driven the stock price up.
</li>
<li>
On December 24, the board of Can-Fite BioPharma approved a 1-for-3000 reverse stock split. This move led to a 1.7% decline in the company's stock during regular trading hours and a 29% drop in after-hours trading.
</li>
<li>
On December 23, Can-Fite BioPharma released its annual report, warning investors about the risk factors the company faces, including the resurgence of the COVID-19 pandemic and the impact of the war between Israel and Hamas on its business. The biotechnology sector has performed strongly recently, and the patent approval has boosted the stock price.
</li>
</ol>
A SPAC III Acquisition is up 49.03% in pre-market trading, with no significant news recently. The trading is active with clear capital flow, and considering the sector and industry trends, the stock shows significant volatility, with specific reasons needing further observation.
Northann is up 35.31% in pre-market trading. Based on recent key news:
<ol>
<li>
On December 23, Northann Corp. released important information through the EDGAR system, possibly involving strategic adjustments or financial data updates, leading to a significant increase in stock price. Source: PUBT
</li>
<li>
On December 24, DBS analyst Pei Hwa Ho reiterated a buy rating on Northann Corp. with a target price of S$1.25, and the analyst's positive assessment boosted market confidence
Source: TipRanks
</li>
</ol>
On December 24th, technical sentiment signals indicated a sell, but the market still showed a strong upward trend in Northann's stock price, reflecting investors' optimistic expectations for the company's future. Source: PUBT The market is optimistic about Northann's future performance

AMRZ

WETO

Amrize pre-market up 16.38%; Webus pre-market down 9.06%; Can-Fite BioPharma pre-market up 64.23%; A SPAC III Acquisition pre-market up 49.03%; Northann pre-market up 35.31%

Pre-market hot trades in US stocks: Amrize up 16.38% in pre-market; Webus down 9.06% in pre-market